Table 1 Demographic factors in patients receiving erenumab
Participant characteristics | |
|---|---|
%female | 81/98 (82.7%) |
Mean age, SD (range) | 50.4, 12.4 (18–75) |
Mean, SD (range) number of years with migraine | 19.6, 13 (3–58) |
Mean, SD (range) number of trialled migraine-specific oral preventive drugs | 5.5, 1.8 (1–9) |
Previous trial of greater occipital nerve injections | 80/98 (81.6%) |
Previous trial of intravenous dihydroergotamine | 18/98 (18.4%) |
Previous trial of peripheral neurostimulation device | 32/98 (32.7%) |
Depression (based on PHQ-9 score >=10) | 81/98 (82.7%) |
Severe impact of headaches (HIT-6 >=60) | 92/98 (93.8%) |
Triptan overuse (>= 10 days/month) | 38/98 (38.8%) |
Other analgesic overuse (>=15 days/month) | 43/98 (43.9%) |
‘Resistant migraine’ by EHF criteria | 98/98 (100%) |